Our Team
Aethox has a highly skilled leadership team of experts, combining clinical, scientific, and managerial knowledge, with a demonstrated history of success in developing and delivering targeted oncology treatments.
Chair, Charles Spicer
Charles Spicer has over 25 years’ experience as a director, chair and adviser to companies especially in the medtech and life sciences industries. He currently serves as the Chair of EMV Capital Plc, Korn Wall Limited and Cryogenx and as a board adviser to The Surgical Group. He is also a trustee of several charities. He previously chaired Creo Medical Group plc, IXICO plc and a panel for the UK Department of Health's Invention for Innovation (i4i) program. Charles was previously Chief Executive of MDY Healthcare plc, a strategic healthcare investment firm. Prior to that, he served as Head of Healthcare Corporate Finance at Numis Securities and Nomura International. Charles holds a PhD from London University and an MA from Cambridge University, both in History.
Head of Chemistry, Khondaker Miraz Rahman
Miraz Rahman is a Professor of Medicinal Chemistry at King’s College London, with extensive expertise in both early- and late-stage drug discovery. He graduated as a pharmacist from the Faculty of Pharmacy at the University of Dhaka, Bangladesh, in 1996. After three years in the industry, he transitioned to academia, completed his PhD in synthetic medicinal chemistry at the London School of Pharmacy (now UCL School of Pharmacy), and worked as a CRUK Research Fellow for three years. In 2012, he joined King’s College London as a Lecturer and was subsequently promoted to Chair in Medicinal Chemistry in 2021. He is currently Head of the Drug Discovery Research Division at King’s College London. Miraz is committed to translating innovative laboratory research into commercialization and patient care. He holds 20 patents as an inventor and has co-founded several university spin-out companies, including Pheon Therapeutics, a clinical-stage company developing first-in-class antibody-drug conjugates for the treatment of solid tumours.
Head of Biology, James Arnold
James Arnold is Professor of Tumour Immunology at King’s College London, with over 20 years of experience in Immunology research. He earned his DPhil from the University of Oxford and completed his postdoctoral research at the University of Cambridge, where he also became a Fellow of both the Cancer Research Institute, NY, and Clare Hall. In 2012, James established the Tumour Immunology Group at King’s College London, where his team focuses on developing innovative therapeutic strategies for cancer treatment. He has served on the Grants Committees of major UK cancer charities and was the 2023 Wade F.B. Thompson CLIP Investigator at the Cancer Research Institute, NY.
Chief Medical Officer, James Spicer
James Spicer is Professor of Experimental Cancer Medicine at King’s College London and a Consultant in Medical Oncology at Guy’s and St Thomas’ Hospitals. With extensive experience in delivering novel therapeutics to cancer patients, he leads the Phase I Trials Unit at King’s Health Partners. James graduated from the University of Oxford and earned a PhD from the Institute of Cancer Research, UK. He has also held a range of Director positions in both academic and commercial settings.